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Abstract: Hermansky-Pudlak syndrome (HPS) is a heterogeneous disorder combining oculocuta-
neous albinism (OCA) and a platelet function disorder of varying severity as its most prominent
features. The genes associated with HPS encode for different BLOC- (biogenesis of lysosome-related
organelles complex) complexes and for the AP-3 (adaptor protein-3) complex, respectively. These
proteins are involved in maturation, trafficking, and the function of lysosome-related organelles
(LROs) such as melanosomes and platelet δ-granules. Some patients with different types of HPS
can develop additional complications and symptoms like pulmonary fibrosis, granulomatous colitis,
and immunodeficiency. A new type of HPS has recently been identified associated with genetic
alterations in the BLOC1S5 gene, which encodes the subunit Muted of the BLOC-1 complex. Our
aim was to unravel the genetic defect in two siblings with a suspected HPS diagnosis (because of
OCA and bleeding symptoms) using next generation sequencing (NGS). Platelet functional analysis
revealed reduced platelet aggregation after stimulation with ADP and a severe secretion defect in
platelet δ-granules. NGS identified a novel homozygous essential splice site variant in the BLOC1S5
gene present in both affected siblings who are descendants of a consanguine marriage. The patients
exhibited no additional symptoms. Our study confirms that pathogenic variants of BLOC1S5 cause
the recently described HPS type 11.
Keywords: Hermansky-Pudlak syndrome; HPS-11; bleeding tendency; hypopigmentation;
oculocutaneous albinism; BLOC1S5
1. Introduction
Hermansky-Pudlak syndrome (HPS, OMIM Phenotype Series—PS203300) is a rare het-
erogeneous disorder affecting maturation, trafficking, and the function of lysosome-related
organelles (LROs) such as melanosomes and platelet δ-granules. HPS is thus characterized
by oculocutaneous albinism (OCA) and a bleeding diathesis of variable severity. Addi-
tionally, cell type specific LROs may be affected, leading to pulmonary fibrosis (aberrant
alveolar macrophage or mast cell function), to granulomatous colitis (intestinal granulomas
and inflammatory cells), and immunodeficiency (cytotoxic T-cell-granules).
Since its first description in 1959 by Hermansky and Pudlak [1], knowledge of the
clinical symptoms, underlying genes and pathomechanism of HPS has deepened over the
last few decades. Next-generation sequencing in particular has increased the number of
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diagnosed patients, since molecular genetic analysis can assess a multi-gene panel much
faster than gene-by-gene direct sequencing. Up until 2020, alterations in 10 genes had been
reported to cause HPS type 1 to type 10; however, Pennamen et al. reported just recently
pathogenic variants in the BLOC1S5 gene (OMIM *607289) associated with a new type of
HPS named type 11 (#619172) [2].
All HPS genes are involved in the biogenesis of four ubiquitously expressed multi-
subunits complexes: BLOC-1 (biogenesis of lysosome-related organelles complex-1), BLOC-2,
BLOC-3 and AP-3 (adaptor protein-3) [3].
The genes DTNBP1, BLOC1S3, BLOC1S6 and BLOC1S5 code for subunits of the
BLOC-1 complex and are associated with the HPS-7, HPS-8, HPS-9 disorders and HPS-11,
respectively. Main phenotypical presentations of the few patients described so far are OCA
and a bleeding diathesis.
The HPS3, HPS5 and HPS6 genes code for the three subunits of the BLOC-2 com-
plex [4], leading to HPS-3, -5, and HPS-6 [5–8]. Patients with a BLOC-2 deficiency often
present with a milder phenotype such as OCA with variable hypopigmentation and mod-
erate bleeding diathesis.
HPS1 and HPS4 code for the two subunits of the BLOC-3 complex. Patients with
HPS-1 and HPS-4 are at risk of developing pulmonary fibrosis with an onset as young
adults or middle age, respectively [9–13].
Defects of the adaptor protein-3 (AP-3) are due to alterations in the AP3B1 (HPS-2)
and AP3D1 (HPS-10) genes. Interestingly, patients with an HPS-2 or HPS-10 defect suffer
from immunodeficiency in addition to OCA and bleeding diathesis [14–16]. HPS-2 patients
carry the risk of developing pulmonary fibrosis with an onset in childhood [17]. Right
before HPS-11 was first described, Huizing et al. summarized the reports of patients with
HPS types 1-10 worldwide in their mutation update [18].
The BLOC-1 complex contains eight subunits: pallidin, cappuccino, dysbindin, snapin,
muted, BLOS1, BLOS2, and BLOS3 [19,20], with a subcomplex organization of pallidin-
cappuccino-BLOS1 and dysbindin-snapin-BLOS2, respectively [21]. Besides the ability
to sort proteins in mammalian cells, the BLOC-1 complex is involved in recycling of
endosomes bringing together the actin and microtubule cytoskeleton [22].
Very few patients with defects in the subunits dysbindin (DTNBP1, HPS-7) [6,23–26],
BLOS3 (BLOC1S3, HPS-8) [6,27–29], pallidin (BLOC1S6, HPS-9) [30–34] and muted (BLOC1S5,
HPS-11) [2,35] have been described so far. However, reports of pathogenic variants in
the BLOC1S4 gene, which encodes the subunit cappuccino known to be associated with
an HPS phenotype in mice, will likely follow [36]. Snapin and BLOS1 knockout mice are
inviable [37,38].
In 2002, Zhang et al. showed in the muted mouse model that the gene encodes a
protein involved in regulating vesicle trafficking. Mice with mutations in the muted gene
(orthologue the human BLOC1S5) exhibit a Hermansky-Pudlak phenotype [39]. The human
BLOC1S5 gene encodes three transcripts: Isoform 1 (NM_201280.3; 2659 nucleotides) encod-
ing for the longest protein (NP_958437.1; 187 aa), and Isoform 2 (NM_001199322.1; 2798 nt)
and 3 (NM_001199323.1; 2565 nt) coding for NP_001186251.1 (123 aa) and NP_001186252.1
(90 aa), respectively (https://www.ncbi.nlm.nih.gov/; accessed on 17 August 2021). After
the first description of two unrelated patients with homozygous pathogenic variants in the
BLOC1S5 gene by Pennamen et al., a patient from China was described with a homozygous
nonsense variant in BLOC1S5 [35]. These three reported HPS-11 patients presented with
moderate OCA (creamy skin and lighter hair than their parents, nystagmus and retinal
hypopigmentation) and mild to moderate bleeding diathesis.
Here we report the case of two brothers with a suspected HPS diagnosis for over a
decade. However, a pathogenic/likely pathogenic variant in the direct sequencing of the
candidate genes for HPS-1–HPS-8 had not been identified. Now next generation sequencing
(NGS) using a multi gene panel finally identified a novel homozygous likely pathogenic
variant in the BLOC1S5 gene leading to a molecular genetic diagnosis of HPS-11.
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2. Materials and Methods
2.1. Ethic Statement
This study was approved by our local ethics committee. Informed consent was
obtained from the patients and/or their parents before genetic analysis was performed.
2.2. Patients
The patients (P1 and P2) are two brothers from Uzbekistan who presented with
OCA and bleeding symptoms in our outpatient clinic about 10 years ago during a visit
to Germany. The parents are related and have black hair and darker skin color than their
2 children. Both brothers presented with creamy skin and light-blond hair. The older
brother’s ophthalmological features (P1) comprised nystagmus, retinal hypopigmentation,
iris transillumination, optic nerve decussation anomalies on visual evoked potentials,
strabismus, photophobia, and visual acuity of 20/200 in both eyes. The younger brother
(P2) presented with nystagmus, ocular albinism, including retinal hypopigmentation, iris
transillumination, photophobia, and visual acuity of 20/200 and 20/100 in the right and
left eyes, respectively. P1 reported epistaxis lasting a few hours three to four times a year;
circumcision did not trigger increased bleeding complications. His brother (P2) reported
epistaxis twice a year, getting more severe over time; he suffered from extensive bleeding
after a circumcision at the age of 5 years.
2.3. Platelet Count and Platelet Aggregometry Analyses
Platelet count was measured via an automated cell counter (Sysmex KX-21 N, Norder-
stedt, Germany). Platelet-rich plasma (PRP) and platelet-poor plasma (PPP) were obtained
by centrifugation of citrate-anticoagulated blood samples. Using the APACT 4 (LABiTec,
Ahrensburg, Germany), platelet aggregometry analyses were performed after stimulation
with collagen (2 µg/mL; Takeda, Linz, Austria), adenosine diphosphate (ADP; 4 µmol/L;
Sigma-Aldrich, St. Luis, MO, USA), epinephrine (8 µmol/L; Sanofi-Aventis, Frankfurt,
Germany) and ristocetin (1.2 mg/mL; American Biochemical and Pharmaceutical Ltd.,
Frankfurt, Germany).
2.4. Flow Cytometry Analyses
Flow cytometry analyses were performed using FACSCalibur (Becton Dickinson,
Heidelberg, Germany) [40]. Diluted PRP aliquots (5 × 107 platelets/mL) were fixed
and stained with FITC-labeled monoclonal surface antibody against CD41 (GPIIb/IIIa-
complex), CD42a (GPIb/IX) and CD42b (GPIb) (Coulter, Immunotech, Marseille, France).
FITC-labeled anti-VWF (Bio-Rad AbD Serorech, Puchheim, Germany) and Alexa Fluor
488-labeled anti-fibrinogen (Invitrogen, Waltham, MA USA) were used to stain the platelets.
In the presence of 1.25 mM Gly Pro-Arg-Pro (Bachem, Bubendorf, Switzerland) diluted
PRP (5× 107 platelets/mL) was stimulated with several concentrations of thrombin (0, 0.05,
0.1, 0.2, 0.5 and 1 U/mL; Siemens Healthineers, Marburg, Germany) to conduct the CD62
and CD63 expression analyses. The platelets were also stained with monoclonal FITC-
labeled anti-CD62 (P-selectin) and anti-CD63 antibodies (lysosomal membrane associated
glycoprotein 3, LAMP-3; Immunotech, Marseille, France).
2.5. Molecular Genetic Analyses
To extract genomic DNA from EDTA-blood, we applied standard procedures and
the Blood and Cell Kit by Qiagen (Qiagen GmbH, Hilden, Germany). Panel sequencing
(95 genes including all 11 HPS-genes) was performed in both patients using a custom
designed Nextera Rapid Enrichment Kit (Illumina, San Diego, California/USA) followed
by sequencing on a MiSeq (Illumina). SeqPilot (JSI medical systems) was used for data anal-
yses. The variants were exported and filtered by allele frequency and serious consequences.
We used supporting software ALAMUT® (v.2.15), pathogenicity prediction (CADD; Com-
bined Annotation Dependent Depletion), occurrence in population and disease databases
(HGMD public version, Huizing HPS Mutation update [18]) to classify the variants. These
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analyses were conducted following the ACMG (American College of Medical Genetics)
guidelines [41]. Sanger sequencing was performed for confirmation. BLOC1S5 exon 2 and
intronic boundaries were amplified using the following primers (F, forward; R, reverse):
F- 5′- TCT CTT AGT GGG GAA GGG AGA GAG T-3′ and R- 5′-CCC TAG AGC AGG
CAC CAG AAC T-3′. Array-CGH (comparative genomic hybridization) analyses were
performed using the SNP array Infinium® CytoSNP-850K (Illumina, San Diego, CA, USA)
according to the manufacturer’s instructions.
3. Results
3.1. Platelet Aggregometry Revealed Impaired Platelet Aggregation and Platelet Flow Cytometry
Showed a Delta-Granule Secretion Defect
P1 and P2 presented with normal platelet count (247 G/L and 249 G/L, respectively).
Light transmission aggregometry revealed only slight impaired aggregation after stimu-
lation with all agonists for P2, whereas P1 showed only slight altered aggregation after
stimulation with ADP (Table 1).
Table 1. Platelet aggregometry analyses for P1 and P2.
Agonist Max. Aggregation [%]P1
Max. Aggregation [%]
P2
Collagen (2.0 µg/mL) 83 70 desaggregation
Ristocetin (1.2 mg/mL) 85 87 desaggregation
ADP (4 µmol/L) 69 desaggregation 77 desaggregation
Epinephrine (8 µmol/L) 72 64
Normal max. aggregation: >70%.
Interestingly, flow cytometry analysis showed severely reduced CD63 expression
after activation with thrombin, indicating a delta-granule secretion defect in the platelets
(Figure 1A,B).
Figure 1. Upper panel: Platelet granule secretion after stimulation with thrombin (concentrations: 0,
0.05, 0.1, 0.2, 0.5, and 1.0 U/mL) for the two brothers using flow cytometry. Severely impaired δ-granule
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secretion indicated by reduced platelet CD63 expression in P1 (A) and P2 (B) compared to the
healthy control. Data are expressed as logarithmic arbitrary units (logAU) of anti-CD63-stained
unstimulated and thrombin-stimulated platelets. Lower panel: Sanger Sequencing for confirmation
of BLOC1S5:c.[113-1G > A];[113-1G > A]. Reverse chromatograms for patient P1 (C) and P2 (D).
3.2. NGS Identified a Novel Homozygous Likely Pathogenic Variant in BLOC1S5
Molecular genetic analysis using a multi-gene panel was performed for the brothers.
Average sequencing depth over all genes for the two patients investigated was 99% for
20 × coverage and 98%/99% for 100 ×, respectively. The brothers shared a novel homozy-
gous essential splice site variant c.113-1G > A in BLOC1S5 (NM_201280.2) confirmed via
direct sequencing (Figure 1C,D). This variant is located at the acceptor splice site of in-
tron 1. The consequence of this change is not predictable, but a skip of exon 2 is very likely.
There was no patient’s mRNA available to prove the splice effect; however, the ALAMUT®
included splice defect prediction tools (MaxEnt., NNSPLICE, and SSF) predicted a splice
defect (−100%). The CADD score is 34, a score of greater or equal 20 indicates the 1% most
deleterious substitutions. This novel likely pathogenic variant is not listed in the gnomAD
(v2.1) public database in either its homozygous or heterozygous state, or in dbSNP. Array-
CGH analyses ruled out compound heterozygosity with a deletion and confirmed the most
likely biallelic state of the variant. Overall ACMG pathogenicity criteria are: PVS1, PM2,
PP3, PP4 = “Pathogenic”. Because we could not further characterize the splice defect, we
classified the variant as likely pathogenic.
4. Discussion
Our study identified a novel homozygous essential splice site variant located at
the acceptor splice site of intron 1 in BLOC1S5 in two brothers presenting with an HPS
phenotype. Novel variants in a gene in which loss of function (LOF) is a known disease
mechanism and that lead to serious consequences for the encoded protein (null variant:
nonsense, frameshift, canonical ± 1 or 2 splice sites, initiation codon, single- or multi-exon
deletion) are considered, with very strong evidence (PVS1), to be pathogenic. All three
human BLOC1S5 transcripts include exon 1–2 and therefore are affected by the splice site
variant. Because the brothers live in Uzbekistan, we could not obtain further material for
cDNA sequencing or Western blot analysis of platelets to further investigate the splice
defect. However, the alteration (c.133-1G > A) at the canonical acceptor splice site (AG
→ AA) is considered to lead to abnormal splicing. The software SeqPilot’s copy number
analysis revealed no alteration indicating a potential deletion of BLOC1S5 exons. Because
we did not have DNA from the related parents for segregation analysis, we performed array-
CGH analyses to exclude a potential allelic deletion masking homozygosity. Moreover, NGS
analysis of the two brothers’ DNA did not detect pathogenic/likely pathogenic variants
in any of the other HPS genes in a homozygous or heterozygous state. In addition, NGS
did not reveal pathogenic/likely pathogenic variants in the genes associated with Griscelli
syndrome type 1-3 (MYO5A, RAB27A, MLPH) or Chediak–Higashi syndrome (LYST).
Regarding the three reported patients so far with HPS-11 (a 20-yr-old female originat-
ing from French Flanders, a 39-yr-old female originating from Slovenia, and a male patient
from China), the authors identified either a deletion of two exons or a 1-basepair deletion
leading to a frameshift/protein truncation or a premature STOP codon [2,35]. Together
with the canonical splice site variant identified in our study patients, there are now 5 HPS
patients identified with BLOC1S5 null variants (multi-exon deletion, nonsense, frameshift,
canonical ± 1 or 2 splice sites). All alterations lead to serious consequences for the protein.
The patients reported so far suffer from hypopigmentation of the skin and hair,
ophthalmologic symptoms such as photophobia, and poor visual acuity. Two patients’
bleeding diathesis was mild: bleeding after minor traumas in the Chinese patient; and
the French Flanders patient’s bleeding diathesis was not apparent until the molecular
genetic diagnosis was made. The latter patient had initially reported no signs of bleeding
diathesis; however, after counseling her history revealed easy bruising, epistaxis once or
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twice a year, and gingival bleeding. The female patient originating from Slovenia suffered
from epistaxis, easy or unexplained bruising, and excessive blood loss after deliveries,
surgery, and dental extraction. Menorrhagia improved via contraception. She also reported
abdominal pain, dyspnea, and recurrent infections (pneumonia, herpes, conjunctivitis) [2].
The two male patients in our study presented with OCA and mild to moderate bleeding
diathesis similar to the French Flanders patient.
Molecular diagnosis is essential for genetic counseling. Furthermore, comprehensive
diagnostics help to improve the treatment after trauma-induced bleeding and prevent
post-surgical bleeding.
Patients with defects in other BLOC-complexes, e.g., in the BLOC-3 complex or AP3-
complex, can develop pulmonary fibrosis, granulomatous colitis, and immunodeficiency.
Most of the few patients with a BLOC-1 deficiency do not develop such features. However,
individual patients have been reported with suspected granulomatous colitis (HPS-7) [26]
or lymphocyte-predominant Hodgkin’s lymphoma (HPS-8) [29], an association previously
described in HPS-2 patients [42]. Milder features like mild primary immunodeficiency or
gastrointestinal problems have been reported for a few patients as well. Two unrelated
HPS-9 patients (from Italy and Pakistan) share the same homozygous nonsense mutation
in PLDN (HGNC approved gene symbol: BLOC1S6:c.232C>T (p.Q78*)). Badolato et al.’s
Italian patient presented a mild primary immunodeficiency coinciding with leukocytopenia
and recurrent cutaneous infections. Their patient’s anomalies were not as prominent as
those in HPS-2 patients [30]. Their 17-year-old patient did not suffer hemorrhagic episodes,
and platelet aggregation tests were thus normal. They conducted no further investigation
of the platelet delta granule secretion. The Pakistani patient, a 4-yr-old female, suffered
from OCA, photophobia, nystagmus, prolonged bleeding, and platelet dysfunction. The
girl also suffered gastrointestinal distress including, nausea, vomiting, abdominal pain,
and diarrhea [34]. Mild leukocytopenia with no history of recurrent infections has been
reported for another HPS-9 patient from Japan [33]. The granule secretion defect in
leucocytes generally seems to be so mild that patients with BLOC-1 deficiencies stand out
primarily because of their OCA. The bleeding severity in patients with a BLOC-1 deficiency
varies, and females, in particular, may have increased problems because of menorrhagia or
extensive post-partum bleeding) [26]. We summarized all reported cases of HPS-7, HPS-8,
HPS-9, and HPS-11 in Table 2.




gDNA/mRNA Amino Acid Variant Type dbSNP (rs)/ClinVar Ethnic Background(Age, Gender) References
c.177G>A p.Trp59* Nonsense rs727502866 Caucasian (77y, F) Lowe et al. (2013), [26]
Portuguese (48y, M),
Paraguayan (6y, M) Li et al. (2003), [25]
Portuguese (siblings:
26y, M; 56yr, F)
Bryan et al. (2017), [24]
Bastida et al. (2019), [23]
c.307C>T p.Gln103* Nonsense rs104893945
Portuguese (18y, F) Bastida et al. (2019), [23]













c.131C>A p.Ser44* Nonsense rs281865115 Iranian (6y, M) Cullinane et al. (2012), [27]
c.338_341del p.Leu113Argfs*15 Indel SCV001192839 Brazilian (10y, M) Pennamen et al. (2021), [29]
c.385_403del p.Ser129Glnfs*90 Indel SCV001192837
1 case Lasseaux et al. (2018), [6]
North African (15, M)
and his affected
sibling
Pennamen et al. (2021), [29]
c.444_467del p.Gln150_Ala157del Indel rs754841982SCV001192838
1 case Lasseaux et al. (2018), [6]
Portuguese (12y, M) Pennamen et al. (2021), [29]














Indel - Syrian (4m, F) Michaud at al. (2021), [32]
Italian (17y, F), Badolato et al. (2012), [30]
c.232C>T p.Gln78* Nonsense rs201348482 Pakistani (4y, F) Yousaf et al. (2016), [34]
BLOC1S6
(NM_012388.3)
HPS-9 c.285_286dup p.His96Leufs*22 Indel - Japanese (52y, F) Okamura et al. (2018), [33]
















(20, F) Pennamen et al. (2020), [29]
c.113-1G>A Splice site - Uzbekistan (siblings:19y, M; 16y, M) This study
c.181del p.Val61* Nonsense rs774712389 Chinese(unknown, M) Zhong et al. (2021), [35]
c.345del p.Val116Serfs19* Indel - Slovenia (39y, F) Pennamen et al. (2020), [29]
Abbreviations: y, years; M, male; F, female, *, termination. 1 listed in the NIH HPS cohort referred by Dr. Rosenzweig and in the Mutation
update from Huizing et al. (2020).
The brothers in our study, now 19 and 16 years old, have not developed any signs
of immunodeficiency, pulmonary or intestinal problems so far. However, their diagnosis
of suspected Hermansky-Pudlak syndrome in 2012 led to a better understanding of their
symptoms, and therefore, to better care for them (skin and eye care, awareness of a bleeding
disorder concerning possible surgery). The most serious problem was the untreated visual
defect. Tinted corrective glasses, 20% for inside use and 80% for outside, helped to reduce
glare sensitivity. NGS now led to the diagnosis HPS type 11. This will help to better assess
the disease not only for these patients, but for assessing different types of the Hermansky-
Pudlak syndrome as well. In this ultra-rare disease, every patient report is important,
so that knowledge can be deepened with respect to the HPS-11 phenotype. If a genetic
diagnosis of a BLOC-1 deficiency is made, patients should also be carefully examined for
slight defects in lysosome-related organelles in other cell types in order to characterize these
rare diseases more precisely. A description of these brothers’ phenotype and genotype will
help us gain more insights in the only recently described HPS-11.
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